Kang Tong, Chen Jiamin, Wan Weijun, Pang Jinshu, Wen Rong, Bai Xiumei, Li Lipeng, Pan Yunjing, He Yun, Yang Hong
Department of Medical Ultrasound, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Guangxi Zhuang Autonomous Region, Nanning, China.
Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor/Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Guangxi Medical University, Nanning, China.
Mol Biotechnol. 2025 May;67(5):2046-2059. doi: 10.1007/s12033-024-01181-y. Epub 2024 May 23.
TAT, a widely used treatment for HCC, can exacerbate the progression of residual HCC. The present study investigated the mechanism of action of PLK1 following ITA of HCC. The PLK1 levels in HCC were determined using qRT-PCR from clinical patient samples, IHC from tissue microarray, and data from globally high-throughput data and microarrays. The PLK1 levels and their effect on the biological phenotype of heat-stress HCC cells were evaluated through in vitro experiments. We detected PLK1 abnormal expression in HCC models of nude mice subjected to ITA. We detected the effects of different PLK1 expression levels on EMT pathway proteins. PLK1 exhibited an overexpression in HCC tissues with an SMD of 1.19 (3414 HCC and 3036 non-HCC tissues were included), distinguishing HCC from non-HCC effectively (AUC = 0.9). The qRT-PCR data from clinical HCC patient samples and IHC from HCC tissue microarray results also indicated an overexpressed level. In the incomplete ablation models, an increased PLK1 expression was found in both heat-stress cells and subcutaneous tumors. The upregulation of PLK1 following ITA was found to enhance the malignancy of HCC and exacerbate the proliferation, migration, and invasion of residual HCC cells, whereas PLK1 knockdown suppressed the biological malignancy of HCC cells. Meanwhile, PLK1 has different regulatory effects on various EMT pathway proteins. PLK1 promotes the progression of residual HCC by activating EMT pathway after ITA, which might provide a novel idea for the treatment and prognosis of residual HCC.
经动脉化疗栓塞术(TAT)是一种广泛用于治疗肝癌的方法,但它会加剧残留肝癌的进展。本研究调查了肝癌经动脉化疗栓塞术后 polo 样激酶 1(PLK1)的作用机制。通过对临床患者样本进行定量逆转录聚合酶链反应(qRT-PCR)、对组织芯片进行免疫组化(IHC)以及利用全球高通量数据和芯片数据,测定肝癌组织中的 PLK1 水平。通过体外实验评估 PLK1 水平及其对热应激肝癌细胞生物学表型的影响。我们在接受经动脉化疗栓塞术的裸鼠肝癌模型中检测到 PLK1 异常表达。我们检测了不同 PLK1 表达水平对上皮-间质转化(EMT)通路蛋白的影响。PLK1 在肝癌组织中呈过表达,标准化均数差(SMD)为 1.19(纳入 3414 例肝癌组织和 3036 例非肝癌组织),能有效区分肝癌与非肝癌(曲线下面积[AUC]=0.9)。临床肝癌患者样本的 qRT-PCR 数据以及肝癌组织芯片的免疫组化结果也表明 PLK1 表达水平升高。在不完全消融模型中,热应激细胞和皮下肿瘤中均发现 PLK1 表达增加。研究发现,经动脉化疗栓塞术后 PLK1 的上调增强了肝癌的恶性程度,加剧了残留肝癌细胞的增殖、迁移和侵袭,而 PLK1 基因敲低则抑制了肝癌细胞的生物学恶性程度。同时,PLK1 对各种 EMT 通路蛋白具有不同的调节作用。PLK1 通过在经动脉化疗栓塞术后激活 EMT 通路促进残留肝癌的进展,这可能为残留肝癌的治疗和预后提供新思路。